The panel also discussed the success of combining teclistamab and daratumumab for functional high-risk patients who historically experience poor outcomes.

The panel discussed combining trispecifics with mezigdomide, noting the strong activity and improved tolerability of targeting BCMA and CD38. They also discussed how mezigdomide might reverse T-cell exhaustion, while cautioning that careful treatment sequencing is necessary because mezigdomide is highly immune-activating.

The panel also discussed the therapeutic potential of these combinations. Dr. Banerjee highlighted the role of CELMoDs in post-CAR T care, noting that “if you find a drug that’s well-tolerated, like a cell mod, that may be what you need to keep those patients in remission.”